MedTrace Logo

Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension

NCT03269877 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2017-09-01

No results posted yet for this study

Summary

The spleen could be considered a neglected organ. To date, it has been deemed an ancillary organ in portal hypertension or an organ localization in lymphoproliferative diseases. Hypersplenism is a common disorder characterized by an enlarged spleen which causes rapid and premature destruction of blood cells. It can result from any splenomegaly. It is most common with splenomegaly secondary to portal hypertension and hematological disorders. Portal Hypertension is an important cause of splenomegaly in most tropical countries This work will involve a series of studies aiming to:

1. Assess the prevalence and pattern of hypersplenism, and grade the severity of cytopenias in patients with cirrhosis and portal hypertension.
2. Elucidate the relationship between hypersplenism, in these patients, and:

1. The severity of liver cirrhosis as assessed by Child's and the Model of End-stage Liver Disease (MELD) scores.
2. The presence and grade of gastroesophageal varices as assessed by upper endoscopy.
3. The presence of hepatocellular carcinoma
4. Portal hemodynamics and portal vein thrombosis as assessed by Doppler Ultrasound.
3. Test the hypothesis that leucopenia in cirrhotic patients may be caused, at least in part, by apoptosis of polymorphnuclear leucocytes.

Conditions

  • Hypersplenism

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-10-01
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269877 on ClinicalTrials.gov